Brain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
ONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.
The increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Accuracy of current guidelines for genetic testing of breast cancer patients has been recently challenged by a pair of studies suggesting that these guidelines may miss as many patients with pathogenic variants (or genetic mutations) as they may catch.
Atezolizumab is an immune-checkpoint inhibitor, which has been approved by the US Food and Drug Administration (FDA) in various combinations for a number of cancer types in recent years.
The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia.
Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.
Alan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer.